title: Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments.
abstract: BACKGROUND
  Despite extensive clinical experience with onabotulinumtoxinA, few data exist on patient satisfaction or safety with continuous treatment.
  
  
  OBJECTIVE
  This international multicenter study evaluated patient satisfaction and safety with long-term continuous facial aesthetic treatment with onabotulinumtoxinA.
  
  
  METHODS
  Retrospective chart review with a cross-sectional design was used to assess onabotulinumtoxinA treatment, including dosing, concomitant facial aesthetic medications and procedures, and adverse events (AEs). Validated Facial Line Satisfaction Questionnaire, Self-Perception of Age measure, and Facial Line Outcomes questionnaire instruments, and a de novo questionnaire were used to determine patient satisfaction.
  
  
  RESULTS
  A total of 207 patients consisted of the intent-to-treat population, with 194 in the per protocol analyses. Patients received a total of 4,402 glabellar treatments over a mean of 9.1 years, with a mean dose of 21.6 U per treatment. Overall, 92.3% of patients were mostly or very satisfied. Among the 89.7% of patients who reported looking younger, the mean perceived age was 6.9 years younger. Documented AEs were infrequent, mostly mild in severity, and declined in frequency over time.
  
  
  CONCLUSIONS
  This population was self-selecting as they chose to continue treatment for 5 or more years to be eligible.
  
  
  CONCLUSIONS
  Continuous treatment with onabotulinumtoxinA for a mean of 9.1 years was associated with very high patient satisfaction.
authors.affiliation: *Hospital Do Servidor Publico Municipal, Sao Paulo, Brazil; †Carruthers Clinical Research, Vancouver, British Columbia, Canada; ‡Aesthetic Solutions, Chapel Hill, North Carolina; §Goldman, Butterwick, Fitzpatrick, Groff and Fabi: Cosmetic Laser Dermatology, San Diego, California; ‖Allergan, Inc., Irvine, California.
authors.forename: Ada
authors.initials: A
authors.lastname: Trindade de Almeida
authors.forename: Jean
authors.initials: J
authors.lastname: Carruthers
authors.forename: Sue Ellen
authors.initials: SE
authors.lastname: Cox
authors.forename: Mitchel P
authors.initials: MP
authors.lastname: Goldman
authors.forename: Sarah
authors.initials: S
authors.lastname: Wheeler
authors.forename: Conor J
authors.initials: CJ
authors.lastname: Gallagher
mesh_terms: D000368:Aged; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D003357:Cosmetic Techniques; D003430:Cross-Sectional Studies; D005260:Female; D005546:Forehead; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D012189:Retrospective Studies; D015595:Skin Aging
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A